Algert Global LLC lessened its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 14.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,412 shares of the medical research company’s stock after selling 4,432 shares during the period. Algert Global LLC’s holdings in PRA Health Sciences were worth $1,936,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PRAH. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares during the period. Carroll Financial Associates Inc. raised its holdings in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after purchasing an additional 790 shares during the period. Comerica Bank bought a new stake in shares of PRA Health Sciences in the 3rd quarter worth approximately $214,000. Trustmark National Bank Trust Department bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth approximately $225,000. Finally, Aperio Group LLC bought a new stake in shares of PRA Health Sciences in the 2nd quarter worth approximately $233,000. Hedge funds and other institutional investors own 98.49% of the company’s stock.

A number of equities research analysts recently commented on the stock. Mitsubishi UFJ Financial Group assumed coverage on shares of PRA Health Sciences in a report on Friday. They issued an “overweight” rating and a $102.00 price target on the stock. BidaskClub raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Thursday. Barclays began coverage on shares of PRA Health Sciences in a report on Monday, December 11th. They set an “overweight” rating and a $94.00 target price on the stock. Mizuho set a $87.00 target price on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Friday, December 1st. Finally, SunTrust Banks reissued a “buy” rating and set a $101.00 target price on shares of PRA Health Sciences in a report on Friday, October 27th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $90.46.

In other news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.10% of the company’s stock.

Shares of PRA Health Sciences Inc (PRAH) opened at $90.25 on Friday. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences Inc has a 1-year low of $53.47 and a 1-year high of $90.43. The stock has a market cap of $5,720.00, a price-to-earnings ratio of 32.07, a price-to-earnings-growth ratio of 1.51 and a beta of 0.40.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. equities research analysts forecast that PRA Health Sciences Inc will post 3.2 earnings per share for the current fiscal year.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/pra-health-sciences-inc-prah-shares-sold-by-algert-global-llc/1767358.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.